MPG.eBooks - Search Results

Cover Image

21

The use of antivirals for influenza prophylaxis : a review of the clinical effectiveness

by Chao, Yi-Sheng, Spry, Carolyn
Published 2017

CADTH

Cover Image

22

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

23

Entyvio (Vedolizumab)

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

24

Long-term use of ranibizumab for the treatment of age-related macular degeneration : a review of the clinical and cost-effectiveness and guidelines

Published 2014

Canadian Agency for Drugs and Technologies in Health

Cover Image

25

Non-invasive methods for diagnosis and monitoring of liver fibrosis in patients with chronic hepatitis B and C : a review of diagnostic accuracy, clinical effectiveness, cost-effec...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Cover Image

26

Human growth hormone treatment for adult growth hormone deficiency : a review of the clinical effectiveness, safety, cost-effectiveness, and guidelines

Published 2015

CADTH Rapid Response Service

Cover Image

27

Idarucizumab for reversing anticoagulation in adults treated with dabigatran : a review of the clinical effectiveness, cost-effectiveness, and guidelines

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

28

Reslizumab (Cinqair)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

29

Seasonal influenza immunization of health care workers for the prevention of influenza in patients : a review of the clinical effectiveness

by Seal, Kelsey, Spry, Carolyn
Published 2017

Canadian Agency for Drugs and Technologies in Health

Cover Image

30

Omalizumab treatment for adults and children with allergic asthma : a review of the clinical effectiveness, cost-effectiveness, and guidelines

Published 2015

Canadian Agency for Drugs and Technologies in Health

Cover Image

31

Human growth hormone treatment for Prader-Willi syndrome in adolescent and adult patients: clinical evidence, safety, and guidelines

Published 2015

CADTH Rapid Response Service

Cover Image

32

Storage, handling, and administration of expressed human breast milk : a review of guidelines

Published 2016

Canadian Agency for Drugs and Technologies in Health

Cover Image

33

Somatropin (Genotropin) for subcutaneous injection : the treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed

Published 2014

CADTH

Cover Image

34

CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris -- Alexion Pharma Canada Corp.) : indication : adult patients with refractory generalized myasthenia gravis

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

35

CADTH Canadian Drug Expert Committee recommendation: Eculizumab (Soliris - Alexion Pharma Canada Corp.) : indication : the treatment of neuromyelitis optica spectrum disorder (NMOS...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

36

Clinical and economic review report: Vedolizumab (ENTYVIO SC) Takeda Canada Inc. : indication: Crohn disease

Published 2021

Canadian Agency for Drugs and Technologies in Health

Cover Image

37

Non-invasive methods for diagnosis and monitoring of liver fibrosis in patients with chronic hepatitis B and C : a review of diagnostic accuracy, clinical effectiveness, cost-effec...

Published 2015

Canadian Agency for Drugs and Technologies in Health

Cover Image

38

Clinical review report: Burosumab (Crysvita) (Kyowa Kirin limited) : indication: for the treatment of x-linked hypophosphatemia in adult and pediatric patients one year of age and...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

39

Clinical review report: Eculizumab (Soliris) : Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravis

Published 2020

Canadian Agency for Drugs and Technologies in Health

Cover Image

40

Pharmacoeconomic report: Ofatumumab (Kesimpta) (Novartis Pharmaceuticals Canada Inc.) : indication: multiple sclerosis, relapsing-remitting

Published 2021

Canadian Agency for Drugs and Technologies in Health

1
2
3
4
5
6